This is a summary of the results of a study called PHAROS. This study looked at combination treatment with encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®). This combination of medicines was studied in people with metastatic non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Metastatic means that the cancer has spread to other parts of the body. All people in this study had a type of NSCLC that has a change in a gene called BRAF termed a BRAF V600E mutation. A gene is a part of the DNA that has instructions for making things that your body needs to work, and the BRAF V600E mutation contributes to the growth of the lung cancer.This Plain Language Summary of Publication article (PLSP) from Future Oncology looks at the results of a study called PHAROS. The study looked at how well a combination treatment of encorafenib and binimetinib could treat people with metastatic mon-small-cell lung cancer (NSCLC).

Visit the Future Medicine using the link to read the article.

This PLSP is based on an original article called ‘Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer’ and was published in the Journal of Clinical Oncology.

Visit ASCO Publications using the link to read the article.